Ingenol Mebutate
Cat. No.：YN310337
| 产品名称: | Ingenol Mebutate |
| CAS No.: | 75567-37-2 |
| Chemical Name: | 2Z-methyl-2-butenoic acid, (1aR,2S,5R,5aS,6S,8aS,9R,10aR)-1a,2,5,5a,6,9,10,10a-octahydro-5,5a-dihydroxy-4-(hydroxymethyl)-1,1,7,9-tetramethyl-11-oxo-1H-2,8a-methanocyclopenta[a]cyclopropa[e]cyclodecen-6-yl ester |
| Synonyms: | 巨大戟醇甲基丁烯酸酯; Ingenol 3-angelate; PEP005 |
| 分子量: | 430.53 |
| 分子式: | C₂₅H₃₄O₆ |
| SMILES: | C/C=C(C)\C(O[C@H]1C(C)=C[C@]23[C@]1(O)[C@H](O)C(CO)=C[C@@](C3=O)([H])[C@@]4([H])[C@@](C4(C)C)([H])C[C@H]2C)=O |
| 存储: | Please store the product under the recommended conditions in theCertificate of Analysis. |
| 运输: | Room temperature in continental US; may vary elsewhere. |
| 产品描述: | Ingenol Mebutate 是Euphorbia peplus中的活性成分，为PKC的调节剂，对 PKC-α，PKC-β，PKC-γ，PKC-δ 和 PKC-ε 的Ki值分别为 0.3，0.105，0.162，0.376 和 0.171 nM。 |
| IC50和靶点: | [{name:"PKC-β:0.105 nM (Ki)"},{name: "PKC-γ:0.162 nM (Ki)"},{name: "PKC-ε:0.171 nM (Ki)"},{name: "PKC-α:0.3 nM (Ki)"},{name: "PKC-δ:0.376 nM (Ki)"}] |
| In Vitro: | |
| In Vivo: | |
| Clinical Trial: | |
| Solvent & Solubility: |
Ogbourne, S.M., Suhrbier, A., Jones, B., et al.Antitumor activity of 3-ingenyl angelate: Plasma membrane and mitochondrial disruption and necrotic cell deathCancer Res.64(8),2833-2839(2004)
Gillespie, S.K., Zhang, X.D., and Hersey, P.Ingenol 3-angelate induces dual modes of cell death and differentially regulates tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in melanoma cellsMol. Cancer Ther.3(12),1651-1658(2004)
Li, L., Shukla, S., Lee, A., et al.The skin cancer chemotherapeutic agent ingenol-3-angelate (PEP005) is a substrate for the epidermal multidrug transporter (ABCB1) and targets tumor vasculatureCancer Res.70(11),4509-4519(2010)
Hasler, C.M., Acs, G., and Blumberg, P.M.Specific binding to protein kinase C by ingenol and its induction of biological responsesCancer Res.52(1),202-208(1992)
Lebwohl, M., Swanson, N., Anderson, L.L., et al.Ingenol mebutate gel for actinic keratosisN. Engl. J. Med.366(11),1010-1019(2012)
Micali, G., Lacarrubba, F., Nasca, M.R., et al.Topical pharmacotherapy for skin cancer. Part I. PharmacologyJ. Am. Acad. Dermatol.70(6),965.e961-956.e912(2014)
